Abstract
During neutrophil recovery following hematopoietic stem cell transplantation, a constellation of symptoms and signs including fever, erythrodermatous skin rash, and noncardiogenic pulmonary edema often occur. These clinical findings have usually been referred to as engraftment syndrome, or, reflecting the manifestations of increased capillary permeability, capillary leak syndrome. While described most often following autologous stem cell transplantation, a similar clinical syndrome has been observed followed allogeneic stem cell transplantation. Distinction from graft-versus-host disease in the allogeneic setting however, has been difficult. Recent experience with non-myeloablative conditioning for stem cell transplantation, however, reveals that an engraftment syndrome independent of GVHD may occur. In some cases, this engraftment syndrome may be a manifestation of a host-versus-graft reaction (graft rejection). While cellular and cytokine interactions are believed to be responsible for these clinical findings, a distinct effector cell population and cytokine profile have not been defined. Engraftment syndromes are likely associated with an increased transplant-related mortality, mostly from pulmonary and associated multi-organ failure. Corticosteroid therapy is often dramatically effective for engraftment syndrome, particularly for the treatment of the pulmonary manifestations. A proposal for a more uniform definition of engraftment syndrome has been developed in order to allow for a reproducible method of reporting of this complication and for evaluating prophylactic and therapeutic strategies. Bone Marrow Transplantation (2001) 27, 893–898.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Lee C, Gingrich RD, Hohl RJ, Ajram KA . Engraftment syndrome in autologous bone marrow and peripheral stem cell transplantation Bone Marrow Transplant 1995 16: 175–182
Ravoet C, Feremans W, Husson B et al. Clinical evidence for an engraftment syndrome associated with early and steep neutrophil recovery after autologous blood stem cell transplantation Bone Marrow Transplant 1996 18: 943–947
Edenfield W, Moores LK, Goodwin G, Lee N . An engraftment syndrome in autologous stem cell transplantation related to mononuclear cell dose Bone Marrow Transplant 2000 25: 405–409
Kawano C, Muroi K, Kuribara R et al. Engraftment syndrome after autologous peripheral blood stem cell transplantation with high numbers of peripheral blood stem cells followed by granulocyte colony-stimulating factor administration Bone Marrow Transplant 2000 25: 228–229
Cahill R, Spitzer TR, Mazumder A . Marrow engraftment and clinical manifestations of capillary leak syndrome Bone Marrow Transplant 1996 18: 177–184
Nurnberger W, Willers R, Burdach S, Gobel U . Risk factors for capillary leakage syndrome after bone marrow transplantation Ann Hematol 1997 74: 221–224
Moreb J, Kubilis PS, Mullins DL et al. Increased frequency of autoaggression syndrome associated with autologous stem cell transplantation in breast cancer patients Bone Marrow Transplant 1997 19: 101–106
Miller C, Hayashi R, Vogelsang GB et al. Aseptic shock syndrome after bone marrow transplantation Blood 1992 80: 140a
Haire W, Ryby E, Gordon B et al. Multiple organ dysfunction syndrome in bone marrow transplantation J Am Med Assoc 1995 274: 1289–1295
Colby C, McAfee S, Sackstein R et al. Engraftment syndrome following non-myeloablative conditioning therapy and HLA-matched bone marrow transplantation for hematologic malignancy Blood 2000 96: 520a
Khan S, Gaa R, Hutcheson C et al. Engraftment syndrome in breast cancer patients after BM/peripheral blood stem cell transplant is associated with poor long-term survival Blood 2000 96: 332a
Powles R, Morgenstern G, Kay H et al. Mismatched family donors for bone-marrow transplantation as treatment for acute leukemia Lancet 1983 19: 612–615
Powles R, Pedrazzini A, Crofts M et al. Mismatched family bone marrow transplantation Semin Hematol 1984 21: 182–187
Sykes M, Preffer F, Saidman SL et al. Mixed lymphohematopoietic chimerism is achievable following non-myeloablative therapy and HLA-mismatched donor marrow transplantation Lancet 1998 353: 1755–1759
Spitzer T, McAfee S, Sackstein R et al. Haploidentical donor bone marrow transplantation for advanced hematologic malignancy following non-myeloablative preparative therapy: role of in vivo T cell depletion with anti-thymocyte globulin or anti-CD2 monoclonal antibody therapy (MEDI-507) Blood 2000 96: 841a
Jadus M, Wepsic HT . The role of cytokines in graft-versus-host reactions and disease Bone Marrow Transplant 1992 10: 1–14
Antin J, Ferrara L . Cytokine dysregulation and acute graft-versus-host disease Blood 1992 80: 2964–2968
Rabinowitz J, Petros WP, Stuart AR, Peters WP . Characterization of endogenous cytokine concentrations after high-dose chemotherapy with autologous bone marrow support Blood 1993 81: 2452–2459
Salat C, Holler E, Schleuning M et al. Levels of the terminal complement complex, C3a-desArg and C1-inhibitor in adult patients with capillary leak syndrome following bone marrow transplantation Ann Hematol 1995 71: 271–274
Ferrara J, Levy R, Chao NJ . Pathophysiologic mechanisms of acute graft-vs-host disease Biol Blood Marrow Transplant 1999 5: 347–356
Takatsuka H, Takemoto Y, Yamada S et al. Complications after bone marrow transplantation are manifestations of systemic inflammatory response syndrome Bone Marrow Transplant 2000 26: 419–426
Giralt S, Estey E, Albitar M et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy Blood 1997 89: 4531–4536
Slavin S, Nagler A, Naparstek E et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases Blood 1998 91: 756–763
Spitzer T, McAfee S, Sackstein R et al. Intentional induction of mixed chimerism and achievement of antitumor responses after nonmyeloablative conditioning therapy and HLA-matched donor bone marrow transplantation for refractory hematologic malignancies Biol Blood Marrow Transplant 2000 6: 309–320
Holler E, Kolb H, Moller A et al. Increased serum levels of tumor necrosis factor precede major complications of bone marrow transplantation Blood 1990 75: 1011–1016
Allen J, Cooper D, White D, Matthay R . Drug-induced pulmonary disease: part 1: cytotoxic drugs Am Rev Respir Dis 1986 133: 321–340
Wojno K, Vogelsang GB, Beschorner WE, Santos GW . Pulmonary hemorrhage as a cause of death in allogeneic bone marrow recipients with severe acute graft-versus-host disease Transplantation 1994 57: 88–92
Lewis I, DeFor T, Weisdorf DJ . Increasing incidence of diffuse alveolar hemorrhage following allogeneic bone marrow transplantation: cryptic etiology and uncertain therapy Bone Marrow Transplant 2000 26: 539–543
Robbins R, Linder J, Stahl MG et al. Diffuse alveolar hemorrhage in autologous bone marrow transplant recipients Am J Med 1989 87: 511–518
Economou J, Hoban M, Lee JD et al. Production of tumor necrosis factor alpha and interferon gamma in interleukin-2-treated melanoma patients: correlation with clinical toxicity Cancer Immunol Immunother 1991 34: 49–52
Fleischmann J, Shingleton W, Gallagher C et al. Fibrinolysis, thrombocytopenia, and coagulation abnormalities complicating high dose interleukin-2 immunotherapy J Lab Clin Med 1991 117: 76–82
Huber A, Kunkel SL, Todd RF, Weiss SJ . Regulation of transendothelial neutrophil migration by endogenous interleukin-8 Science 1991 254: 99–102
Smith W, Gamble JR, Clark-Lewis I, Vadas MA . Interleukin-8 induces neutrophil transendothelial migration Immunology 1991 72: 65–72
Norton J, Sloane JP . ICAM-1 expression on epidermal keratinocytes in cutaneous graft-versus-host disease Transplantation 1991 51: 1203–1206
Vogelsang G, Hess A . Graft-versus-host disease: new directions for a persistent problem Blood 1994 84: 2061–2067
Nurnberger W, Heying R, Burdach S, Gobel U . C1 esterase inhibitor concentrate for capillary leakage syndrome following bone marrow transplantation Ann Hematol 1997 75: 95–101
Afessa B, Tefferi A, Hoagland HC et al. Outcome of recipients of bone marrow transplants who require intensive-care unit support Mayo Clin Proc 1992 67: 117–122
Paz H, Crilley P, Weinar M, Brodsky I . Outcome of patients requiring medical ICU admission following bone marrow transplantation Chest 1993 104: 527–531
Faber-Langendoen K, Caplan AL, McGlave PB . Survival of adult bone marrow transplant patients receiving mechanical ventilation: a case for restricted use Bone Marrow Transplant 1993 12: 501–507
Marin D, Berrade J, Ferra C et al. Engraftment syndrome and survival after respiratory failure post-bone marrow transplantation Intens Care Med 1998 24: 732–735
Rabitsch W, Staudinger T, Brugger SA et al. Successful management of adult respiratory distress syndrome (ARDS) after high-dose chemotherapy and peripheral blood progenitor cell rescue by non-invasive ventilatory support Bone Marrow Transplant 1998 21: 1067–1069
Metcalf J, Rennard SI, Reed EC et al. Corticosteroids as adjunctive therapy for diffuse alveolar hemorrhage associated with bone marrow transplantation. University of Nebraska Medical Center Bone Marrow Transplant Group Am J Med 1994 96: 327–334
Raptis A, Mavroudis D, Suffredini A et al. High-dose corticosteroid therapy for diffuse alveolar hemorrhage in allogeneic bone marrow stem cell transplant recipients Bone Marrow Transplant 1999 24: 879–883
Acknowledgements
I would like to thank Drs Christine Colby and Megan Sykes for their review of this manuscript and their helpful suggestions.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Spitzer, T. Engraftment syndrome following hematopoietic stem cell transplantation. Bone Marrow Transplant 27, 893–898 (2001). https://doi.org/10.1038/sj.bmt.1703015
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1703015
Keywords
This article is cited by
-
Low incidence of engraftment syndrome following allogeneic hematopoietic cell transplantation with post-transplant cyclophosphamide
Bone Marrow Transplantation (2024)
-
Understanding and treatment of cutaneous graft-versus-host-disease
Bone Marrow Transplantation (2023)
-
Engraftment syndrome after allogeneic stem cell transplantation: a systematic review and meta-analysis
Bone Marrow Transplantation (2023)
-
Safety of romiplostim administered immediately after cord-blood transplantation: a phase 1 trial
Annals of Hematology (2023)
-
Endothelial function testing before conditioning therapy is useful for predicting transplant-related complications after allogeneic hematopoietic cell transplantation
International Journal of Hematology (2023)